Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses. A significantly higher proportion of patients treated with povorcitinib once daily versus placebo achieved ...
Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD ...
"We expect modest weakness today and remain neutral on shares," said Abrahams. The STOP-HS1 and STOP-HS2 studies met their primary endpoint at Week 12, with both 45 mg and 75 mg doses of povorcitinib.
"We expect modest weakness today and remain neutral on shares," said Abrahams. The STOP-HS1 and STOP-HS2 studies met their primary endpoint at Week 12, with both 45 mg and 75 mg doses of povorcitinib.
EUROPE: Swiss Federal Railways is looking at ordering up to 40 high speed trainsets for use on international services to Italy and France, and ’potentially for other destinations such as Barcelona and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback